• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Turkey Pharmaceuticals and Healthcare Report Q1 2013 - Product Image

Turkey Pharmaceuticals and Healthcare Report Q1 2013

  • ID: 2356116
  • December 2012
  • Region: Turkey
  • 98 pages
  • Business Monitor International

FEATURED COMPANIES

  • Abdi Ibrahim
  • Bayer
  • Deva (EastPharma)
  • Local Companies
  • Multinational Companies
  • Pfizer
  • MORE

BMI View: The cooling economic environment and the weakening lira has moderated optimistic forecasts on the Turkish pharmaceutical market, especially as the government is the single largest reimburser of pharmaceuticals, covering 80-85% of total drug expenditure through various insurance and immunisation schemes. Price cutting and public discount decrees announced in November 2011 continue to affect the pharmaceutical market in 2012, as highlighted by the decrease in pharmaceutical spending in the first half of this year.

Headline Expenditure Projections:

- Pharmaceuticals: TRY17.21bn (US$10.24bn) in 2011 to TRY16.35bn (US$9.03bn) in 2012; -
5.0% in local currency terms and -11.8% in US dollar terms. Local currency forecast downgraded from Q412 on account of H112 data.

- Healthcare: TRY83.59bn (US$49.75bn) in 2011 to TRY92.02bn (US$50.84bn) in 2012;
+10.1% in local currency terms and +2.2%in US dollar terms. Local currency forecast slightly increased from Q412 due to increased healthcare investment.

- Medical devices: TRY4.33bn (US$2.58bn) in 2011 to TRY4.78bn (US$2.64bn) in 2012;
+10.3% in local currency terms and +2.4% in US dollar terms. Local READ MORE >

FEATURED COMPANIES

  • Abdi Ibrahim
  • Bayer
  • Deva (EastPharma)
  • Local Companies
  • Multinational Companies
  • Pfizer
  • MORE

Executive Summary 5

SWOT Analysis 7

Turkey Pharmaceuticals And Healthcare Industry SWOT 7

Turkey Political SWOT 8

Turkey Economic SWOT 8

Turkey Political SWOT 9

Pharmaceuticals & Healthcare Risk/Reward Ratings 10
Table: Central And Eastern Europe Pharmaceuticals & Healthcare Risk/Reward Ratings (RRRs), Q113 10

Rewards 11

Risks 11

Turkey – Market Summary 13

Regulatory Regime 14

Intellectual Property Regime 15

Market Access Issues 16

Pricing Regime 17
Table: Turkish Pharmaceutical Pricing Decrees 18

Drug Price Inflation 19

Reimbursement Regime 20
Table: Pharmacist discount related to annual sales revenue (VAT excluded) 21

Industry Developments 22

Epidemiology 22

Non-Communicable Diseases 22

Healthcare Sector 23

Healthcare Insurance 24

Healthcare Infrastructure 25

Healthcare Financing 26

Research & Development 26

Clinical Trials Industry 27

Medical Devices Industry 28

Industry Forecast Scenario 31

Overall Market Forecast 31
Table: Turkey Pharmaceutical Sales, Historical Data And Forecasts 33

Healthcare Market Forecast 34
Table: Turkey Healthcare Expenditure Trends, Historical Data And Forecasts 35
Table: Turkey Government Healthcare Expenditure Trends, Historical Data And Forecasts 36
Table: Turkey Private Healthcare Expenditure Trends, Historical Data and Forecasts 36

Key Growth Factors – Macroeconomic 37
Table: Turkey - Economic Activity 41

Prescription Drug Market Forecast 42
Table: Turkey Prescription Drug Market Indicators, Historical Data And Forecasts 43

Patented Drug Market Forecast 44

Generic Drug Market Forecast 45
Table: Turkey Generics Drug Market Indicators, Historical Data And Forecasts 46

OTC Medicine Market Forecast 47
Table: Turkey Over-The-Counter (OTC) Medicine Market Indicators, Historical Data and Forecasts 48

Pharmaceutical Trade Forecast 49
Table: Turkey Pharmaceutical Trade Data And Forecasts (US$mn) 49
Table: Turkey Pharmaceutical Trade Data And Forecasts (TRYmn) 50

Medical Device Market Forecast 51
Table: Turkey Medical Device Market Indicators, Historical Data And Forecasts 52

Other Healthcare Data 53

Key Risks To BMI’s Forecasts 53

Competitive Landscape 54

Pharmaceutical Sector 54

Domestic Industry 55

Foreign Industry 55

Company Activity 56

Wholesale 57

Retail 58

Company Profiles 60

Local Companies 60

Abdi Ibrahim 60

Eczacibasi Pharmaceuticals 63

Sanovel Pharmaceuticals 66

Deva (EastPharma) 68

Mustafa Nevzat Ilac Sanayi (MN) Pharmaceuticals 71

Multinational Companies 74

Novartis 74

Pfizer 75

Sanofi 77

GlaxoSmithKline 79

Roche 81

AstraZeneca 83

Bayer 84

Merck & Co 86

Demographic Outlook 88

TURKEY - Population By Age Group 89

TURKEY - Population By Age Group 90

TURKEY - Key Population Ratios 91

TURKEY - Rural and Urban Population 91

Glossary 92

BMI Methodology 94

How We Generate Our Pharmaceutical Industry Forecasts 94

Risk/Reward Ratings Methodology 95

Ratings Overview 95
Table: Pharmaceutical Business Environment Indicators 96

Weighting 97
Table: Weighting Of Components 97

Sources 97

Company Profiles
Local Companies
Abdi Ibrahim
Eczacibasi Pharmaceuticals
Sanovel Pharmaceuticals
Deva (EastPharma)
Mustafa Nevzat Ilac Sanayi (MN) Pharmaceuticals
Multinational Companies
Novartis
Pfizer
Sanofi
GlaxoSmithKline
Roche
AstraZeneca
Bayer
Merck & Co

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos